Imunon (IMNN) Competitors

Verrica Pharmaceuticals (NASDAQ:VRCA) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.

Does the MarketBeat Community prefer VRCA or IMNN?

Verrica Pharmaceuticals received 144 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 63.26% of users gave Verrica Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Verrica Pharmaceuticals	Outperform Votes 167 63.26%	Underperform Votes 97 36.74%
Imunon	Outperform Votes 23 100.00%	Underperform Votes No Votes

Do insiders and institutionals hold more shares of VRCA or IMNN?

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 42.6% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Imunon shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is VRCA or IMNN more profitable?

Imunon has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. Imunon's return on equity of -230.05% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-625.06%	-591.84%	-141.63%
Imunon	N/A	-230.05%	-128.98%

Which has more risk and volatility, VRCA or IMNN?

Verrica Pharmaceuticals has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Imunon has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.

Do analysts rate VRCA or IMNN?

Verrica Pharmaceuticals presently has a consensus target price of $9.50, suggesting a potential upside of 1,836.80%. Imunon has a consensus target price of $21.50, suggesting a potential upside of 2,315.73%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Imunon	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media prefer VRCA or IMNN?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of -0.67 beat Imunon's score of -1.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Negative
Imunon	Negative

Which has stronger earnings and valuation, VRCA or IMNN?

Imunon has lower revenue, but higher earnings than Verrica Pharmaceuticals. Imunon is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$7.57M	5.95	-$67M	-$1.54	-0.32
Imunon	$500K	26.03	-$19.51M	-$1.60	-0.56

Summary

Imunon beats Verrica Pharmaceuticals on 11 of the 18 factors compared between the two stocks.